1.	A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18527, NCT00121836
2.	XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18530, NCT00127933
3.	A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML20592, NCT00502671
4.	Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000574159, CHUL-BIO-COLON, INCA-RECF0356, RECF0356, NCT00559676
5.	OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML21380, NCT00577031
6.	Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435
7.	The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: AG0501CR, NCT00294359
8.	Standard Versus Continuous Capecitabine in Advanced Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: 05/237, NCT00418028
9.	Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to79 Sponsor: Other Protocol IDs: 2007-07-RCT-LCI1, NCT00561522
10.	Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000641309, PACT-7, SRSI-PACT-7, EU-20932, NCT00960284
11.	Phase III Open Label Randomized Study Comparing Capecitabine and Fluorouracil in Combination With Leucovorin Calcium as First Line Chemotherapy in Patients With Advanced and/or Metastatic Colorectal Carcinoma (Summary Last Modified 05/98) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ROCHE-SO14695, NCI-V97-1320
12.	Phase III Randomized Study of Adjuvant Capecitabine Versus Fluorouracil and Low-Dose Leucovorin Calcium in Chemotherapy Naive Patients With Previously Resected Stage III Colon Cancer (Summary Last Modified 12/2001) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: ROCHE-M66001, NCT00009737
13.	Phase III Randomized Study of Bevacizumab With Capecitabine Versus Capecitabine Alone in Women With Previously Treated Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GENENTECH-AVF2119g, GUMC-00299, MSKCC-01008, UAB-0028, UAB-F001009003, NCT00012285
14.	Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 65 and over Sponsor: NCI, Other Protocol IDs: CDR0000068891, U10CA031946, CALGB-49907, ECOG-CALGB-49907, CAN-NCIC-MAC1, SWOG-CALGB-49907, MAC1, NCT00024102
15.	Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: SAKK 44/00, SWS-SAKK-44/00, CECOG/PAN-1.3.001, EU-20142, NCT00030732
16.	Phase III Randomized Study of Gemcitabine With or Without Capecitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: CRUK-GEM-CAP, EU-20116, ISRCTN11513444, NCT00032175
17.	Phase III Randomized Study of Preoperative Chemoradiotherapy Comprising Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin in Patients With Resectable Rectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NSABP-R-04, NCT00058474, CALGB-NSABP-R-04
18.	Phase III Randomized Study of Oxaliplatin and Bevacizumab (Avastin™) With Fluorouracil and Leucovorin Calcium or Capecitabine in Patients With Advanced Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PROLOGUE-SANOFI-ARD5099, SANOFI-ARD5099, NCT00062426
19.	Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-40015, NCT00064181
20.	Phase III Randomized Study of Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab Versus Capecitabine, Oxaliplatin, and Bevacizumab in Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0303, S0303, ECOG-S0303, NCT00070122
21.	Phase III Randomized Study of Leucovorin Calcium and Fluorouracil With or Without Oxaliplatin Versus Capecitabine With or Without Oxaliplatin in Patients With Metastatic Colorectal Adenocarcinoma Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: NCRI-FOCUS2, MRC-CR09, EU-20303, NCT00070213
22.	A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NO16966, NCT00069095
23.	A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NO16967, NCT00069108
24.	Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA163-046, NCT00080301
25.	Phase III Randomized Study of Capecitabine With Versus Without Lapatinib in Women With Refractory Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF100151, UCLA-0403074-01, NCT00078572